202 related articles for article (PubMed ID: 33762012)
1. Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
Pathmanapan S; Ilkayeva O; Martin JT; Loe AKH; Zhang H; Zhang GF; Newgard CB; Wunder JS; Alman BA
Cancer Metab; 2021 Mar; 9(1):13. PubMed ID: 33762012
[TBL] [Abstract][Full Text] [Related]
2. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
4. Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Trovarelli G; Sbaraglia M; Angelini A; Bellan E; Pala E; Belluzzi E; Pozzuoli A; Borga C; Dei Tos AP; Ruggieri P
Clin Orthop Relat Res; 2024 Jan; 482(6):947-56. PubMed ID: 38170705
[TBL] [Abstract][Full Text] [Related]
5. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
6. Distinct IDH1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract][Full Text] [Related]
7. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.
Garrett M; Sperry J; Braas D; Yan W; Le TM; Mottahedeh J; Ludwig K; Eskin A; Qin Y; Levy R; Breunig JJ; Pajonk F; Graeber TG; Radu CG; Christofk H; Prins RM; Lai A; Liau LM; Coppola G; Kornblum HI
Cancer Metab; 2018; 6():4. PubMed ID: 29692895
[TBL] [Abstract][Full Text] [Related]
8. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy.
Schoedel K; Heim T; Duensing A; Lohse I; Presutti L; Belayneh R; Bhogal S; Singh-Varma A; Chang A; Chandran U; Marker D; Szabo-Rogers H; Weiss K
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254737
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
10. In vivo metabolic flux profiling with stable isotopes discriminates sites and quantifies effects of mitochondrial dysfunction in C. elegans.
Vergano SS; Rao M; McCormack S; Ostrovsky J; Clarke C; Preston J; Bennett MJ; Yudkoff M; Xiao R; Falk MJ
Mol Genet Metab; 2014 Mar; 111(3):331-341. PubMed ID: 24445252
[TBL] [Abstract][Full Text] [Related]
11. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
Reitman ZJ; Jin G; Karoly ED; Spasojevic I; Yang J; Kinzler KW; He Y; Bigner DD; Vogelstein B; Yan H
Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3270-5. PubMed ID: 21289278
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
14. Metabolic consequences of oncogenic IDH mutations.
Parker SJ; Metallo CM
Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
[TBL] [Abstract][Full Text] [Related]
17.
Venneker S; Bovée JVMG
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509266
[TBL] [Abstract][Full Text] [Related]
18. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.
Nakagawa M; Yamaguchi M; Endo M; Machida Y; Hattori A; Tanzawa F; Tsutsumi S; Kitabayashi I; Kawai A; Nakatani F
J Bone Oncol; 2022 Jun; 34():100430. PubMed ID: 35493690
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
